Search

Your search keyword '"Berghuis B."' showing total 3 results
Start Over Author "Berghuis B." Publisher wiley-blackwell
3 results on '"Berghuis B."'

2. Epidemiology, pathophysiology and putative genetic basis of carbamazepine- and oxcarbazepine-induced hyponatremia

Author

Apotheek Klinische Farmacie, Brain, Genetica Groep Koeleman, Circulatory Health, Child Health, Berghuis, B, de Haan, G-J, van den Broek, M P H, Sander, J W, Lindhout, D, Koeleman, B P C, Apotheek Klinische Farmacie, Brain, Genetica Groep Koeleman, Circulatory Health, Child Health, Berghuis, B, de Haan, G-J, van den Broek, M P H, Sander, J W, Lindhout, D, and Koeleman, B P C

Published
2016

3. Epidemiology, pathophysiology and putative genetic basis of carbamazepine- and oxcarbazepine-induced hyponatremia.

Author

Berghuis, B., Haan, G. ‐ J., Broek, M. P. H., Sander, J. W., Lindhout, D., and Koeleman, B. P. C.

Subjects
*CARBAMAZEPINE, *EPIDEMIOLOGY, *PUBLIC health, *AMIDES, *HYPONATREMIA
Abstract

The use of carbamazepine ( CBZ) and oxcarbazepine ( OXC) as first-line antiepileptic drugs in the treatment of focal epilepsy is limited by hyponatremia, a known adverse effect. Hyponatremia occurs in up to half of people taking CBZ or OXC and, although often assumed to be asymptomatic, it can lead to symptoms ranging from unsteadiness and mild confusion to seizures and coma. Hyponatremia is probably due to the antidiuretic properties of CBZ and OXC that are, at least partly, explained by stimulation of the vasopressin 2 receptor/aquaporin 2 pathway. No known genetic risk variants for CBZ- and OXC-induced hyponatremia exist, but likely candidate genes are part of the vasopressin water reabsorption pathway. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results